CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade RAPT Therapeutics, Inc. - RAPT CFD

16.11
11.26%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.12
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026235 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026235%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.004012 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004012%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

RAPT Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 14.48
Open* 13.83
1-Year Change* -21.51%
Day's Range* 13.83 - 16.25
52 wk Range 10.47-31.45
Average Volume (10 days) 457.72K
Average Volume (3 months) 7.91M
Market Cap 468.13M
P/E Ratio -100.00K
Shares Outstanding 34.40M
Revenue N/A
EPS -2.88
Dividend (Yield %) N/A
Beta 0.33
Next Earnings Date Mar 12, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 1, 2023 16.11 1.98 14.01% 14.13 16.32 13.76
Nov 30, 2023 14.48 -0.65 -4.30% 15.13 15.84 14.39
Nov 29, 2023 14.97 0.94 6.70% 14.03 15.14 14.03
Nov 28, 2023 14.25 0.39 2.81% 13.86 14.42 13.38
Nov 27, 2023 13.80 0.27 2.00% 13.53 13.93 13.10
Nov 24, 2023 13.66 0.54 4.12% 13.12 14.16 13.12
Nov 22, 2023 13.64 -0.25 -1.80% 13.89 13.98 13.45
Nov 21, 2023 13.59 0.11 0.82% 13.48 13.82 13.27
Nov 20, 2023 13.92 -0.15 -1.07% 14.07 14.72 13.80
Nov 17, 2023 14.10 0.93 7.06% 13.17 14.34 13.17
Nov 16, 2023 13.17 1.62 14.03% 11.55 13.20 11.49
Nov 15, 2023 12.00 -0.52 -4.15% 12.52 13.09 11.98
Nov 14, 2023 12.60 0.45 3.70% 12.15 13.05 11.97
Nov 13, 2023 12.08 1.10 10.02% 10.98 12.10 10.98
Nov 10, 2023 11.70 0.71 6.46% 10.99 11.82 10.45
Nov 9, 2023 11.43 -2.04 -15.14% 13.47 13.59 10.98
Nov 8, 2023 13.76 -0.33 -2.34% 14.09 14.09 13.37
Nov 7, 2023 14.11 0.51 3.75% 13.60 14.19 13.47
Nov 6, 2023 13.78 -1.49 -9.76% 15.27 15.46 13.78
Nov 3, 2023 15.45 0.85 5.82% 14.60 16.26 14.60

RAPT Therapeutics, Inc. Events

Time (UTC) Country Event
Tuesday, March 12, 2024

Time (UTC)

12:30

Country

US

Event

Q4 2023 Rapt Therapeutics Inc Earnings Release
Q4 2023 Rapt Therapeutics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 1.527 3.813 5.042 0 0
Total Operating Expense 87.322 73.022 58.256 43.629 36.947
Selling/General/Admin. Expenses, Total 20.24 16.037 12.771 8.719 5.18
Research & Development 67.082 56.985 45.485 34.91 31.767
Operating Income -85.795 -69.209 -53.214 -43.629 -36.947
Other, Net 1.957 0.005 1.312 1.292 0.8
Net Income Before Taxes -83.838 -69.204 -51.902 -42.337 -36.147
Net Income After Taxes -83.838 -69.204 -52.892 -42.997 -36.147
Net Income Before Extra. Items -83.838 -69.204 -52.892 -42.997 -36.147
Total Extraordinary Items
Net Income -83.838 -69.204 -52.892 -42.997 -36.147
Income Available to Common Excl. Extra. Items -83.838 -69.204 -52.892 -42.997 -36.147
Income Available to Common Incl. Extra. Items -83.838 -69.204 -52.892 -42.997 -36.147
Diluted Net Income -83.838 -69.204 -52.892 -42.997 -36.147
Diluted Weighted Average Shares 32.5404 27.3903 24.1343 22.7504 22.7504
Diluted EPS Excluding Extraordinary Items -2.57643 -2.52659 -2.19157 -1.88995 -1.58885
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS -2.57643 -2.52659 -2.19157 -1.88995 -1.58885
Revenue 1.527 3.813 5.042
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0.886
Revenue 0 0 0 0 0.886
Total Operating Expense 28.364 31.562 24.431 21.678 19.795
Selling/General/Admin. Expenses, Total 6.722 5.988 4.977 5.079 5.436
Research & Development 21.642 25.574 19.454 16.599 14.359
Operating Income -28.364 -31.562 -24.431 -21.678 -18.909
Other, Net 3.084 2.291 1.48 0.443 -0.275
Net Income Before Taxes -25.28 -29.271 -22.951 -21.235 -19.184
Net Income After Taxes -25.28 -29.271 -22.951 -21.235 -19.184
Net Income Before Extra. Items -25.28 -29.271 -22.951 -21.235 -19.184
Net Income -25.28 -29.271 -22.951 -21.235 -19.184
Income Available to Common Excl. Extra. Items -25.28 -29.271 -22.951 -21.235 -19.184
Income Available to Common Incl. Extra. Items -25.28 -29.271 -22.951 -21.235 -19.184
Diluted Net Income -25.28 -29.271 -22.951 -21.235 -19.184
Diluted Weighted Average Shares 38.3287 38.2805 35.7158 33.6843 31.1403
Diluted EPS Excluding Extraordinary Items -0.65956 -0.76464 -0.6426 -0.63041 -0.61605
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.65956 -0.76464 -0.6426 -0.63041 -0.61605
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 252.694 192.973 115.598 80.506 65.062
Cash and Short Term Investments 249.068 189.654 111.51 77.383 63.798
Cash & Equivalents 38.946 24.027 24.918 77.383 63.798
Prepaid Expenses 3.626 3.319 4.088 3.123 1.264
Total Assets 266.209 198.636 118.969 84.602 69.61
Property/Plant/Equipment, Total - Net 9.479 2.741 2.982 3.707 4.159
Property/Plant/Equipment, Total - Gross 17.728 10.425 10.064 9.766 9.128
Accumulated Depreciation, Total -8.249 -7.684 -7.082 -6.059 -4.969
Other Long Term Assets, Total 4.036 2.922 0.389 0.389 0.389
Total Current Liabilities 14.224 9.595 11.742 9.256 4.643
Accounts Payable 3.365 1.999 2.383 1.143 1.771
Accrued Expenses 10.827 6.326 4.935 3.642 2.488
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.032 1.27 4.424 4.471 0.384
Total Liabilities 21.043 12.256 14.79 11.481 5.612
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 6.819 2.661 3.048 2.225 0.969
Total Equity 245.166 186.38 104.179 73.121 63.998
Preferred Stock - Non Redeemable, Net 161.111
Common Stock 0.003 0.003 0.002 0.002 0.001
Additional Paid-In Capital 613.073 470.629 319.196 235.049 22.441
Retained Earnings (Accumulated Deficit) -367.884 -284.046 -214.842 -161.95 -118.953
Other Equity, Total -0.026 -0.206 -0.177 0.02 -0.602
Total Liabilities & Shareholders’ Equity 266.209 198.636 118.969 84.602 69.61
Total Common Shares Outstanding 34.2543 29.5551 24.7734 21.833 22.7504
Redeemable Preferred Stock 0 0 0 0
Short Term Investments 210.122 165.627 86.592
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 187.138 207.417 234.587 252.694 197.894
Cash and Short Term Investments 184.777 204.998 231.629 249.068 195.436
Cash & Equivalents 54.135 50.164 45.768 38.946 27.706
Short Term Investments 130.642 154.834 185.861 210.122 167.73
Prepaid Expenses 2.361 2.419 2.958 3.626 2.458
Total Assets 199.721 220.756 248.326 266.209 209.489
Property/Plant/Equipment, Total - Net 8.376 9.066 9.525 9.479 8.524
Property/Plant/Equipment, Total - Gross 17.442 17.807 18.073 17.728 16.531
Accumulated Depreciation, Total -9.066 -8.741 -8.548 -8.249 -8.007
Other Long Term Assets, Total 4.207 4.273 4.214 4.036 3.071
Total Current Liabilities 21.849 15.414 21.608 14.224 13.867
Accounts Payable 5.297 2.69 8.941 3.365 4.043
Accrued Expenses 16.499 12.628 12.626 10.827 9.791
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.053 0.096 0.041 0.032 0.033
Total Liabilities 26.921 21.079 27.856 21.043 20.183
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 5.072 5.665 6.248 6.819 6.316
Total Equity 172.8 199.677 220.47 245.166 189.306
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.003 0.003 0.003 0.003 0.003
Additional Paid-In Capital 626.724 622.289 617.283 613.073 534.689
Retained Earnings (Accumulated Deficit) -453.806 -422.435 -397.155 -367.884 -344.933
Other Equity, Total -0.121 -0.18 0.339 -0.026 -0.453
Total Liabilities & Shareholders’ Equity 199.721 220.756 248.326 266.209 209.489
Total Common Shares Outstanding 34.3604 34.3521 34.2897 34.2543 29.8862
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -83.838 -69.204 -52.892 -42.997 -36.147
Cash From Operating Activities -70.771 -61.026 -40.491 -35.474 -32.953
Cash From Operating Activities 1.047 0.996 1.123 1.33 1.237
Non-Cash Items 13.355 11.48 8.934 2.06 1.173
Changes in Working Capital -1.335 -4.298 2.344 4.133 0.784
Cash From Investing Activities -45.49 -81.347 -87.435 -0.843 -3.5
Capital Expenditures -0.845 -0.755 -0.398 -0.888 -3.5
Cash From Financing Activities 131.18 141.482 75.461 49.902 52.734
Issuance (Retirement) of Stock, Net 131.18 141.482 75.461 49.902 52.734
Net Change in Cash 14.919 -0.891 -52.465 13.585 16.281
Cash Taxes Paid 0 0.99 0.66
Other Investing Cash Flow Items, Total -44.645 -80.592 -87.037 0.045
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -29.271 -83.838 -60.887 -39.652 -20.468
Cash From Operating Activities -18.602 -70.771 -47.922 -30.773 -15.578
Cash From Operating Activities 0.299 1.047 0.795 0.535 0.261
Non-Cash Items 3.237 13.355 10.595 7.084 3.27
Changes in Working Capital 7.133 -1.335 1.575 1.26 1.359
Cash From Investing Activities 25.308 -45.49 -4.22 13.379 23.837
Capital Expenditures -0.759 -0.845 -0.796 -0.715 -0.149
Other Investing Cash Flow Items, Total 26.067 -44.645 -3.424 14.094 23.986
Cash From Financing Activities 0.116 131.18 55.821 50.57 0.132
Issuance (Retirement) of Stock, Net 0.116 131.18 55.821 50.57 0.132
Net Change in Cash 6.822 14.919 3.679 33.176 8.391
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Fidelity Management & Research Company LLC Investment Advisor 10.1451 3485663 598841 2023-06-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 9.9754 3427371 -129091 2023-06-30 LOW
The Column Group LP Venture Capital 7.802 2680621 0 2023-06-30 LOW
Perceptive Advisors LLC Private Equity 6.6607 2288493 -3115 2023-06-30 MED
Deep Track Capital LP Hedge Fund 5.796 1991403 986842 2023-10-23 MED
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.7025 1959275 13508 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 5.6499 1941204 365431 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.9538 1702045 62999 2023-06-30 LOW
Great Point Partners, LLC Hedge Fund 4.2643 1465151 110000 2023-06-30 HIGH
OrbiMed Advisors, LLC Investment Advisor/Hedge Fund 3.6413 1251070 0 2023-06-30 LOW
T. Rowe Price Investment Management, Inc. Investment Advisor 3.6166 1242587 10804 2023-06-30 LOW
Kingdon Capital Management, L.L.C. Hedge Fund 2.9105 1000000 124016 2023-06-30 HIGH
Braidwell LP Hedge Fund 2.8651 984400 984400 2023-06-30 HIGH
Morgan Stanley & Co. LLC Research Firm 2.2524 773890 7297 2023-06-30 MED
Fidelity Institutional Asset Management Investment Advisor 2.0514 704826 -864192 2023-06-30 LOW
Euclidean Capital, L.L.C. Investment Advisor 1.6626 571233 138333 2023-06-30 MED
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.5832 543950 15395 2023-06-30 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 1.574 540786 83162 2023-06-30 LOW
Alphabet, Inc. Venture Capital 1.5725 540270 0 2023-06-30 LOW
Wong (Brian Russell) Individual Investor 1.413 485470 6220 2023-03-30

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

RAPT Therapeutics, Inc. Company profile

About Rapt Therapeutics Inc

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Utilizing its drug discovery and development engine, the Company develops selective small molecules that are designed to modulate the critical immune responses underlying these diseases. Its two lead drug candidates each target C-C motif chemokine receptor 4 (CCR4). Its lead oncology drug candidate, FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors. FLX475 is in Phase I/II clinical trials. Its lead inflammation drug candidate, RPT193, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells) into inflamed tissues.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Rapt Therapeutics Inc revenues decreased 24% to $3.8M. Net loss increased 31% to $69.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 27% to $51.7M (expense), General and administrative increase of 31% to $11.4M (expense).

Industry: Bio Therapeutic Drugs

561 Eccles Ave
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

Income Statement

  • Annual
  • Quarterly

News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023
GBP

UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

10:48, 21 November 2023

People also watch

US100

16,001.20 Price
+0.470% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

XRP/USD

0.63 Price
+0.640% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

BTC/USD

39,538.60 Price
-0.260% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Gold

2,072.25 Price
+1.760% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee 0.0111%
Overnight fee time 22:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading